[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401706":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":49,"locations":54,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":79,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hepatocellular Carcinoma (HCC)",null,"Patients with Hepatocellular Carcinoma (HCC)",[13],"Other: Physician's choice according to patient's needs.",{"label":15,"type":10,"description":16,"interventionNames":17},"Cholangiocarcinoma (CCC)","Patients with Cholangiocarcinoma (CCC)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","Physician's choice according to patient's needs.","Routine care as per site standard.",[15,9],[25,29,32,35,38,41,44,47],{"name":26,"affiliation":27,"role":28},"Thomas Berg, Prof.Dr.","Leipzig","STUDY_CHAIR",{"name":30,"affiliation":31,"role":28},"Peter R. Galle, Prof.Dr.","Mainz",{"name":33,"affiliation":34,"role":28},"Wolf P. Hofmann, Prof.Dr.","Berlin",{"name":36,"affiliation":37,"role":28},"Achim Kautz","Köln",{"name":39,"affiliation":40,"role":28},"Philippe Pereira, Prof.Dr.","Heilbronn",{"name":42,"affiliation":43,"role":28},"Karin Potthoff, Dr.","Freiburg im Breisgau",{"name":45,"affiliation":46,"role":28},"Jan Schröder, PD Dr.","Mülheim an der Ruhr",{"name":48,"affiliation":43,"role":28},"Robert Thimme, Prof.Dr.",[50],{"name":5,"role":51,"phone":52,"phoneExt":10,"email":53},"CONTACT","+49 761 15242-0","info@iomedico.com",[55],{"facility":56,"status":57,"city":58,"state":10,"zip":10,"country":59,"countryCode":60,"cosmosGeoPoint":10,"geoPoint":10,"contacts":61},"Multiple sites all over germany","RECRUITING","Multiple Sites","Germany","DE",[62],{"name":5,"role":51,"phone":63,"phoneExt":10,"email":53},"+49 761 152420",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100401706","liver-cancer-registry-platform-100401706",false,"NCT04510740","Liver Cancer Registry Platform","JADE - Clinical Research Platform on Treatment and Outcome in Patients With Hepatocellular or Cholangiocellular Cancer","JADE","Inclusion criteria:\n\n* Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced\u002Fmetastatic stage\n* Age ≥ 18 years\n* Signed and dated informed consent (IC):\n\n  * For participation in the PRO module: Before primary locoregional therapy or start of first systemic treatment\n  * For no participation in the PRO module: No later than 8 weeks after primary locoregional therapy or start of first systemic treatment\n\nExclusion criteria:\n\nPatients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)","ALL","18 Years",{"count":77,"type":78},1000,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.",[9,83],"Cholangiocarcinoma","2026-06-03",{"date":86,"type":87},"2026-06-04","ACTUAL",{"date":89,"type":87},"2020-08-09",{"date":91,"type":78},"2027-12",{"name":5,"class":6},1]